The MUHC has recently sent letters to heart patients who underwent surgery involving Abbott Trifecta Valves. The letters inform you that advisories have been issued by the United States Food and Drug Administration (FDA) and manufacturer Abbott regarding the devices.
The FDA and Abbott messages, dated February 27, 2023, address the potential risk for early structural valve deterioration. Information is also provided in the letter that was mailed to you by the MUHC. If you have more questions, please contact your doctor or nurse who will help address any concerns you may have at this time.
You can find the FDA and Abbott documents below.